7TM Pharma Enters Collaboration with Ortho-McNeil Pharmaceutical

7TM Pharma A/S has announced that it has entered into an exclusive worldwide license agreement and research collaboration with Ortho-McNeil Pharmaceutical, Inc., a Johnson & Johnson company, to further develop 7TM Pharma's program on novel oral compounds for the treatment of asthma and allergic diseases.

Under the agreement, 7TM Pharma will receive an upfront fee, research funding and milestones, as well as royalties on sales for each compound developed under the collaboration. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. will be responsible for the development of compounds resulting from the collaboration.

The basis for the collaboration is 7TM Pharma's drug discovery platform, Site-Directed Drug Discovery, and one of its resulting drug discovery programs targeting the discovery of novel antagonists to a certain 7-transmembrane receptor.

7TM Pharma A/S is a drug discovery and development company focusing on medicines acting through 7TM receptors. The company is tightly integrating its structure based drug discovery approach, Site-Directed Drug Discovery with traditional medicinal chemistry and peptide insight and has thereby created a drug discovery platform that dramatically accelerates the generation of new drugs targeting 7TM receptors. The company's rich pipeline includes several well advanced programs within its main therapeutic focus area - obesity - as well as other programs on well validated targets in allergy/ inflammation, therapeutic angiogenesis and cardiovascular diseases. 7TM Pharma's other partnerships include agreements with Procter & Gamble Pharmaceuticals Inc., AstraZeneca, and H.Lundbeck A/S.

For further information please contact:

Mette Kirstine Agger,

CEO

Tel: +45 39 25 77 77

Email: mka@7tm.com

Or visit: http://www.7tm.com